Verastem (VSTM) Cash from Financing Activities (2011 - 2026)

Verastem's (VSTM) quarterly Cash from Financing Activities came in at $28.7 million in Q1 2026, down 57.45% year-on-year from $67.4 million in Q1 2025, and down 70.9% quarter-over-quarter from $98.6 million in Q4 2025.

Verastem (VSTM) Cash from Financing Activities (2011 - 2026) Analysis & Trends

Verastem's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $28.7 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities fell 57.45% year-over-year to $28.7 million in Q1 2026; TTM through Mar 2026 was $224.6 million, a 85.04% increase from a year earlier, with the FY2025 full-year figure at $263.3 million, up 380.64% from the prior year.
  • Cash from Financing Activities eased to $28.7 million in Q1 2026 per VSTM's latest filing, from $98.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $98.6 million in Q4 2025 and bottomed at -$891000.0 in Q3 2023.
  • The 5-year median for Cash from Financing Activities is $25.5 million (2022), against an average of $33.3 million.
  • Across the five-year window, Cash from Financing Activities slumped 103.48% in 2023 and jumped 19708.89% in 2025, its largest moves.
  • Year by year, Cash from Financing Activities stood at $25.6 million in 2022, then slumped by 101.74% to -$446000.0 in 2023, then surged by 266.37% to $742000.0 in 2024, then soared by 13186.12% to $98.6 million in 2025, then plunged by 70.9% to $28.7 million in 2026.
  • Per Business Quant, the three latest VSTM Cash from Financing Activities figures stand at $28.7 million (Q1 2026), $98.6 million (Q4 2025), and $17.9 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 30.14 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 68.63 Mn
4 NuCana 279.75 Bn 279.75 Bn - 9,311.16
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 238.74 Mn
10 Verastem 166.09 Mn -31.73 Mn 15.90 Mn 28.69 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 28.69 Mn
Mar 31, 2026 28.69 Mn
Dec 31, 2025 98.58 Mn
Dec 31, 2025 98.58 Mn
Sep 30, 2025 17.88 Mn
Sep 30, 2025 17.88 Mn
Jun 30, 2025 79.42 Mn
Jun 30, 2025 79.42 Mn
Mar 31, 2025 67.43 Mn
Mar 31, 2025 67.43 Mn
Dec 31, 2024 742,000.00
Dec 31, 2024 742,000.00
Sep 30, 2024 53.60 Mn
Sep 30, 2024 53.60 Mn
Jun 30, 2024 -405,000.00
Jun 30, 2024 -405,000.00
Mar 31, 2024 846,000.00
Mar 31, 2024 846,000.00
Dec 31, 2023 -446,000.00
Dec 31, 2023 -446,000.00